Navigation Links
Nanoneedle is small in size, but huge in applications
Date:4/28/2009

CHAMPAIGN, Ill. Researchers at the University of Illinois have developed a membrane-penetrating nanoneedle for the targeted delivery of one or more molecules into the cytoplasm or the nucleus of living cells. In addition to ferrying tiny amounts of cargo, the nanoneedle can also be used as an electrochemical probe and as an optical biosensor.

"Nanoneedle-based delivery is a powerful new tool for studying biological processes and biophysical properties at the molecular level inside living cells," said

Min-Feng Yu, a professor of mechanical science and engineering and corresponding author of a paper accepted for publication in Nano Letters, and posted on the journal's Web site.

In the paper, Yu and collaborators describe how they deliver, detect and track individual fluorescent quantum dots in a cell's cytoplasm and nucleus. The quantum dots can be used for studying molecular mechanics and physical properties inside cells.

To create a nanoneedle, the researchers begin with a rigid but resilient boron-nitride nanotube. The nanotube is then attached to one end of a glass pipette for easy handling, and coated with a thin layer of gold. Molecular cargo is then attached to the gold surface via "linker" molecules. When placed in a cell's cytoplasm or nucleus, the bonds with the linker molecules break, freeing the cargo.

With a diameter of approximately 50 nanometers, the nanoneedle introduces minimal intrusiveness in penetrating cell membranes and accessing the interiors of live cells.

The delivery process can be precisely controlled, monitored and recorded goals that have not been achieved in prior studies.

"The nanoneedle provides a mechanism by which we can quantitatively examine biological processes occurring within a cell's nucleus or cytoplasm," said Yang Xiang, a professor of molecular and integrative physiology and a co-author of the paper. "By studying how individual proteins and molecules of DNA or RNA mobilize, we
'/>"/>

Contact: James E. Kloeppel, Physical Sciences Editor
kloeppel@illinois.edu
217-244-1073
University of Illinois at Urbana-Champaign
Source:Eurekalert

Page: 1 2

Related biology news :

1. Social parasites of the smaller kind
2. Small animal imaging facility is big boon to research
3. Handbook of small grain insects available now
4. New molecular clock from LLNL and CDC indicates smallpox evolved earlier than believed
5. 2007 ozone hole smaller than usual
6. Cilia: small organelles, big decisions
7. Research shows loggerhead sea turtles threatened by small-scale fishing operations
8. Small-scale fishing in Mexico rivals industrial fisheries in accidental turtle deaths
9. Sweet potato shines as new promise for small enterprise and hunger relief in developing countries
10. Identification of a novel class of (not-so) small RNAs
11. Small RNA plays parallel roles in bacterial metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... Through the generous support of the Breast ... Cancer Research (AACR) is pleased to announce the ... Translational Breast Cancer Research. These grants provide ... designed to accelerate the discovery, development, and application ...
... DC Some nanotechnology fanciers suggest that, like ... will flock or clump together. ... risks as nanotechnology manufacturing increases and the number ... nanoparticle expert Andrew Maynard, chief science advisor to ...
... A modified plastic material greatly improves the ability to ... the gas is prepared for use, according to engineers ... analyzed the new plastics performance. Like a sponge ... permits carbon dioxide or other small molecules to go ...
Cached Biology News:AACR, BCRF award inaugural grants in translational breast cancer research 2AACR, BCRF award inaugural grants in translational breast cancer research 3Nanoparticle exposures happen, says expert 2New membrane strips carbon dioxide from natural gas faster and better 2New membrane strips carbon dioxide from natural gas faster and better 3
(Date:6/2/2015)... Through rare discovery of new physics ... is enabling World Scientists to actually see, watch, ... displaying the full nature (position, shape, size, number) of ... Porter, Co-Founder of the Yancy Corporation, says, "Our rare ... They come once in a lifetime, if at all. ...
(Date:6/1/2015)... Chosen for his engaging style ... has been selected as keynote speaker for a ... will deliver his keynote: "Don't Stop Thinking About ... to the American Medical Association, Blue Cross Blue ... Forum on Wireless Healthcare, United Healthcare, IASIS Healthcare, ...
(Date:6/1/2015)... and RARITAN, N.J. ... Development, LLC (Janssen) announced data from the Phase ... improvement in progression-free survival (PFS) with trabectedin (YONDELIS ... advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated ... chemotherapy regimen. SAR3007 is the largest randomized Phase ...
(Date:6/1/2015)... , June 1, 2015  Novartis is highlighting ... of CTL019, an investigational chimeric antigen receptor (CAR) ... the treatment of specific types of hard-to-treat non-Hodgkin ... the University of Pennsylvania,s Perelman School of Medicine ... diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma ...
Breaking Biology Technology:Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... CRANBURY, N.J., Aug. 12 Palatin Technologies, Inc. (NYSE ... of a Phase 1 clinical trial of subcutaneously administered ... male erectile dysfunction (ED) and female sexual dysfunction (FSD). ... blood plasma levels can be obtained without blood pressure ...
... Health care jobs continue ... industry remains at 20,000 monthly, and health care has one of the the lowest unemployment rates ... feeling the economic pinch more and more. , ... (Vocus) August 12, 2009 -- There is a dichotomy between simultaneous job creation and job ...
... Scientists drew fittingly from Roman mythology when they named ... Janus, who is usually depicted as having two faces ... been fascinated by the tantalizing possibilities of these particles ... and many other devices. However, realizing these applications requires ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 2Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 3Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 4The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 2The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 3The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 4Capping a two-faced particle gives duke engineers complete control 2
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Phosphorylcholine hapten is conjugated to BSA protein by use of p-diazonium phenylphosphorylcholine....
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Blue Standard is 3-cyano-7-hydroxycoumarin....
Biology Products: